Cadrenal Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
CAD-1005, a novel IV therapy for HIT, is advancing to phase III after promising phase II results and strong safety data. The drug targets a major unmet need, holds Orphan Drug and Fast Track status, and may have broader applications in diabetes and obesity.
-
The discussion highlighted a portfolio targeting critical gaps in anticoagulation, with VLX-1005 and Tecarfarin advancing for rare, high-risk patients. VLX-1005's novel 12-LOX inhibition approach in HIT, regulatory advantages, and upcoming milestones position it as a key near-term value driver.
Fiscal Year 2025
-
Novel anticoagulant drugs are being developed to address high-risk and orphan indications, with tecarfarin targeting chronic care gaps and frunexian focused on acute care. Key clinical trials for tecarfarin are planned for 2026–2027, and frunexian is advancing towards acute cardiac surgery applications.
-
The discussion highlighted tecarfarin's potential to address unmet needs in rare cardiovascular conditions, especially for LVAD and ESKD with AFib patients where current anticoagulants are inadequate. Key 2025 goals include finalizing the pivotal trial protocol, manufacturing readiness, and leveraging orphan drug status.
Fiscal Year 2024
-
Tecarfarin, a next-generation blood thinner, is positioned to replace warfarin by addressing its metabolic instability and associated risks. Recent clinical data and regulatory progress, along with strategic discussions with Abbott, support a strong outlook for pivotal studies in LVAD patients.
-
Tecarfen, a late-stage anticoagulant, targets patients with LVADs and rare cardiovascular conditions who currently rely on inadequate warfarin therapy. Backed by strong clinical data and orphan/fast track designations, Tecarfen is one pivotal trial away from FDA submission and commercialization.
-
Tecarfarin, a novel oral anticoagulant, is advancing toward pivotal trials for rare cardiovascular conditions, with a lead focus on LVAD patients. Recent Abbott-sponsored data and ongoing collaboration discussions support its unique value, and regulatory engagement is expected to clarify timelines soon.